Facility Design by Leading Architectural Firms
LISBON, Portugal and NEW YORK, Oct. 8 /PRNewswire/ -- Three weeks after awarding two Johns Hopkins University scientists the most prestigious vision award in the world for their research in combating blindness, the Antonio Champalimaud Foundation continued its pioneering work in medical research with the groundbreaking of its 300,000-square-foot research facility. The Champalimaud Foundation Center, named after the late Portuguese businessman and benefactor Antonio Champalimaud, is expected to be not only a cutting edge research facility, but also a magnificent architectural project in a historic section of Lisbon. The center will provide care and research on cancer and neuroscience that will benefit the international medical and scientific community.
By 2030 it is estimated that there will be 20 to 25 million incident cases of cancer around the world, and 13 to 16 million cancer deaths annually. In the US the number of people living with cancer is expected to double from 1.3 to 2.6 million between the years 2000 to 2050, according to the International Agency for Research on Cancer. The Champalimaud Center will attract scientists from all over the world to undertake the most advanced translational research in cancer and neuroscience using a multidisciplinary team approach.
The new center will foster collaboration between world class researchers and renowned cancer specialists. The state-of-the-art facility will foster frontline research in oncology, molecular biology, genetics, immunology, neuroscience and behavior, as well as post-graduate and doctorate programs, and the diagnosis and treatment of neurological and cancer patients.
Signifying the importance of the new center, Portuguese Prime Minister, Jose Socrates, presided, with the Champalimaud Foundation President, Leonor Beleza, over the groundbreaking ceremony. The architect, Charles Correa, addressed the assembly, describing the design of the facility. The ceremony was highlighted by a small robot placing the first stone in the building's foundation. This signified a new and advanced era of scientific exploration and discovery for Portugal. The Center will be built in a historic location, where the Tagus River joins the Atlantic Ocean -- the point from which 15th and 16th -century Portuguese explorers embarked on maritime journeys and discoveries. This location is also symbolic of the new discoveries in the world of science and disease treatment, which are expected to be made at this Center.
Bombay-based firm Charles Correa Associates is the Design Architect, in collaboration with RMJM Hillier as Laboratory and Clinical Design Architects and Consiste of Portugal as the Architect of record. The facility will have Diagnostic, Treatment, and Wellness Centers and an open-air amphitheatre facing the river for public performances. Also, the project will include high-performance buildings that employ optimal energy and resource management. The Champalimaud Center is the first building in a major redevelopment plan to change the face of the Lisbon riverfront. The anticipated inauguration date for the Center is October 5th, 2010.
About the Champalimaud Foundation:
The Champalimaud Foundation supports individual researchers and
research teams working at the cutting edge of medical science. It aims to
stimulate novel theoretical and practical methodologies by utilizing the
experience of both research scientists and medical practitioners,
connecting pure scientific investigation with applied clinical research.
The Champalimaud Foundation aims to maximize the work being done in the
fields of cancer research and neuroscience, including stem cell research
and its clinical applications for Parkinson's and Alzheimer's disease,
diabetes and spinal injury. It is named for Antonio Champalimaud, who was
the richest man in Portugal when he died in 2004, bequeathing a quarter of
his $3.1 billion estate to set up the Foundation. See http://www.fchampalimaud.org
In Europe, Vitor Cunha, +351-9666-19794, firstname.lastname@example.org, all for The Champalimaud Foundation.
|SOURCE The Champalimaud Foundation|
Copyright©2008 PR Newswire.
All rights reserved